Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study

NCT03934684 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03934684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03934684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
September 16, 2019
Completion date
June 27, 2025
Enrollment
101 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed refractory multiple myeloma